Lysate of Probiotic Lactobacillus casei DN-114 001 Ameliorates Colitis by Strengthening the Gut Barrier Function and Changing the Gut Microenvironment

0371857 - MBÚ 2012 RIV US eng J - Journal Article
Zákostelská, Zuzana - Kverka, Miloslav - Klimešová, Klára - Rossmann, Pavel - Mrázek, Jakub - Kopečný, Jan - Hornová, Michaela - Šrůtková, Dagmar - Hudcovic, Tomáš - Rídl, Jakub - Tlaskalová-Hogenová, Helena
Lysate of Probiotic Lactobacillus casei DN-114 001 Ameliorates Colitis by Strengthening the Gut Barrier Function and Changing the Gut Microenvironment.
PLoS ONE. Roč. 6, č. 11 (2011), s. 1-11. ISSN 1932-6203. E-ISSN 1932-6203
R&D Projects: GA ČR(CZ) GAP304/11/1252; GA ČR GD310/08/H077; GA ČR GA305/08/0535; GA ČR GA303/08/0367; GA AV ČR KJB500200904; GA MŠMT 2B06155; GA MZd(CZ) NS10340
Institutional research plan: CEZ:AV0Z50200510; CEZ:AV0Z50520514; CEZ:AV0Z50450515
Keywords : INFLAMMATORY-BOWEL-DISEASE * DEXTRAN SULFATE SODIUM * LACTIC-ACID BACTERIA
Subject RIV: EC - Immunology
Impact factor: 4.092, year: 2011

Probiotic bacteria can be used for the prevention and treatment of human inflammatory diseases including inflammatory bowel diseases (IBD). However, the nature of active components and exact mechanisms of this beneficial effects have not been fully elucidated. Our aim was to investigate if lysate of probiotic bacterium L. casei DN-114 001 (Lc) could decrease the severity of intestinal inflammation in a murine model of IBD.The preventive effect of oral administration of Lc significantly reduces the severity of acute dextran sulfate sodium (DSS) colitis in BALB/c but not in SCID mice. In order to analyze how this beneficial effect interferes with well-known phases of intestinal inflammation pathogenesis in vivo and in vitro, we evaluated intestinal permeability using the FITC-labeled dextran method and analysed tight junction proteins expression by immunofluorescence and PCR
Permanent Link: http://hdl.handle.net/11104/0205278